ReviewJournal of clinical medicine2026
Diagnostic and Therapeutic Strategies for Brain Metastases from Unknown Primary Tumors: A Comprehensive Review.
Review in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain metastases represent a heterogenous group of tumors, with distinct characteristics and prognosis, depending on the primary malignancy and on the patient performance status. In up to 28% of cases, neurological symptoms from a brain metastasis are the initial clinical manifestation of the primary cancer. If the primary neoplasm remains unidentified, patients are diagnosed with Brain Metastases for Cancer of Unknown Primary (BM-CUP). While brain metastases are far more common than primary brain tumors, CUP represents a rare malignancy, accounting for 2-5% of all cancer cases. It is characterized by an aggressive clinical course, rapid metastatic spread, low response rate to chemotherapy, and poor prognosis. Understanding BM-CUP remains a challenge, and being such a rare disease, there is still a significant lack of consensus regarding the management of these patients. Nevertheless, recent progression in diagnostic techniques, immunohistochemistry, and genomic sequencing open a new horizon to personalized therapies in selected cases. However, limitations persist, including biological heterogeneity and limited access to genomic sequencing, often leading to the use of empirical treatment. This review synthesizes recent advancements in the diagnosis and management of BM-CUP, highlighting the importance of a structured therapeutic approach for optimizing survival outcomes and preserving quality of life in this challenging patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.